Top

Endocrine

Published in:

01-04-2020 | Type 2 Diabetes | Meta-Analysis

Circulating TNF receptors and risk of renal disease progression, cardiovascular disease events and mortality in patients with diabetes: a systematic review and meta-analysis

Authors: Dongsheng Cheng, Yang Fei, Pierre-Jean Saulnier, Niansong Wang

Published in: Endocrine | Issue 1/2020

Abstract

Purpose

Inflammation plays an important role in the pathogenesis of diabetes complications. This study aims to assess the association between circulating inflammatory biomarkers TNF receptors (TNFRs) and the risk of renal disease progression, cardiovascular disease (CVD) events, and mortality in patients with diabetes.

Methods

PubMed and Embase databases were comprehensively searched up to March 2019. Data were extracted independently by two reviewers. A random effects model was performed for the pooled analyses.

Results

Five studies in 3316 subjects assessed TNFRs with renal disease in patients with type 1 diabetes and showed both TNFR-1 and TNFR-2 were consistently associated with the renal outcomes. Fourteen studies in 7696 subjects evaluated TNFRs in patients with type 2 diabetes. The pooled risk ratio per doubling increase in TNFR-1 and TNFR-2 for renal disease progression was more than two (2.64 [1.98, 3.52] and 2.23 [1.69, 2.94]). The subgroup analyses and sensitivity analyses further illustrated these results of renal outcome and its robustness. Moreover, higher TNFR-1 and TNFR-2 was also significantly associated with CVD events and mortality in patients with type 2 diabetes.

Conclusions

Circulating TNFR-1 and TNFR-2 are independently associated with higher risk of renal disease progression, CVD events, and mortality in patients with diabetes and might contribute to the clinical risk assessment in the future.

Available only for authorised users

E.W. Gregg, X. Zhuo, Y.J. Cheng, A.L. Albright, K.M. Narayan, T.J. Thompson, Trends in lifetime risk and years of life lost due to diabetes in the USA, 1985–2011: a modelling study. Lancet Diabetes Endocrinol. 2(11), 867–874 (2014). https://doi.org/10.1016/S2213-8587(14)70161-5 CrossRefPubMed

G.B.D. Disease, I. Injury, C. Prevalence, Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet 390(10100), 1211–1259 (2017). https://doi.org/10.1016/S0140-6736(17)32154-2 CrossRef

J.C. Jha, F. Ho, C. Dan, K. Jandeleit-Dahm, A causal link between oxidative stress and inflammation in cardiovascular and renal complications of diabetes. Clin. Sci. 132(16), 1811–1836 (2018). https://doi.org/10.1042/CS20171459 CrossRefPubMed

M.Y. Donath, Targeting inflammation in the treatment of type 2 diabetes: time to start. Nat. Rev. Drug Discov. 13(6), 465–476 (2014). https://doi.org/10.1038/nrd4275 CrossRefPubMed

K.R. Tuttle, F.C. Brosius 3rd, S.G. Adler, M. Kretzler, R.L. Mehta, J.A. Tumlin, Y. Tanaka, M. Haneda, J. Liu, M.E. Silk, T.E. Cardillo, K.L. Duffin, J.V. Haas, W.L. Macias, F.P. Nunes, J.M. Janes, JAK1/JAK2 inhibition by baricitinib in diabetic kidney disease: results from a Phase 2 randomized controlled clinical trial. Nephrol. Dial. Transpl. 33(11), 1950–1959 (2018). https://doi.org/10.1093/ndt/gfx377 CrossRef

P. Vassalli, The pathophysiology of tumor necrosis factors. Annu. Rev. Immunol. 10, 411–452 (1992). https://doi.org/10.1146/annurev.iy.10.040192.002211 CrossRefPubMed

R.S. Al-Lamki, T.N. Mayadas, TNF receptors: signaling pathways and contribution to renal dysfunction. Kidney Int. 87(2), 281–296 (2015). https://doi.org/10.1038/ki.2014.285 CrossRefPubMed

A.C. Carlsson, C. J. Östgren, F. H. Nystrom, T. Länne, P. Jennersjö, A. Larsson, J. Arnlöv, Association of soluble tumor necrosis factor receptors 1 and 2 with nephropathy, cardiovascular events, and total mortality in type 2 diabetes. Cardiovasc. Diabetol. 15(1) (2016). https://doi.org/10.1186/s12933-016-0359-8

M.A. Niewczas, T. Gohda, J. Skupien, A.M. Smiles, W.H. Walker, F. Rosetti, X. Cullere, J.H. Eckfeldt, A. Doria, T.N. Mayadas, J.H. Warram, A.S. Krolewski, T.N.F. Circulating, Receptors 1 and 2 predict ESRD in type 2 diabetes. J. Am. Soc. Nephrol. 23(3), 507–515 (2012). https://doi.org/10.1681/asn.2011060627 CrossRefPubMedPubMedCentral

10.

T. Gohda, M.A. Niewczas, L.H. Ficociello, W.H. Walker, J. Skupien, F. Rosetti, X. Cullere, A.C. Johnson, G. Crabtree, A.M. Smiles, T.N. Mayadas, J.H. Warram, A.S. Krolewski, Circulating TNF receptors 1 and 2 predict stage 3 CKD in type 1 diabetes. J. Am. Soc. Nephrol. 23(3), 516–524 (2012). https://doi.org/10.1681/asn.2011060628 CrossRefPubMedPubMedCentral

11.

S.G. Coca, G.N. Nadkarni, Y. Huang, D.G. Moledina, V. Rao, J. Zhang, B. Ferket, S.T. Crowley, L.F. Fried, C.R. Parikh, Plasma biomarkers and kidney function decline in early and established diabetic kidney disease. J. Am. Soc. Nephrol. 28(9), 2786–2793 (2017). https://doi.org/10.1681/asn.2016101101 CrossRefPubMedPubMedCentral

12.

D.F. Stroup, J.A. Berlin, S.C. Morton, I. Olkin, G.D. Williamson, D. Rennie, D. Moher, B.J. Becker, T.A. Sipe, S.B. Thacker, Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. JAMA 283(15), 2008–2012 (2000)CrossRef

13.

G. A. Wells, B. S. D O'Connell, J. Peterson, V. Welch, M. Losos, P. Tugwell, The Newcastle–Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp. Accessed 10 Sep 2018

14.

H.T. Davies, I.K. Crombie, M. Tavakoli, When can odds ratios mislead? BMJ 316(7136), 989–991 (1998)CrossRef

15.

J.P. Higgins, S.G. Thompson, J.J. Deeks, D.G. Altman, Measuring inconsistency in meta-analyses. BMJ 327(7414), 557–560 (2003). https://doi.org/10.1136/bmj.327.7414.557 CrossRefPubMedPubMedCentral

16.

S. Duval, R. Tweedie, Trim and fill: a simple funnel-plot-based method of testing and adjusting for publication bias in meta-analysis. Biometrics 56(2), 455–463 (2000)CrossRef

17.

I. Shai, M.B. Schulze, J.E. Manson, K.M. Rexrode, M.J. Stampfer, C. Mantzoros, F.B. Hu, A prospective study of soluble tumor necrosis factor-alpha receptor II (sTNF-RII) and risk of coronary heart disease among women with type 2 diabetes. Diabetes Care 28(6), 1376–1382 (2005)CrossRef

18.

C. Forsblom, J. Moran, V. Harjutsalo, T. Loughman, J. Waden, N. Tolonen, L. Thorn, M. Saraheimo, D. Gordin, P.H. Groop, M.C. Thomas; FinnDiane Study, G., Added value of soluble tumor necrosis factor-alpha receptor 1 as a biomarker of ESRD risk in patients with type 1 diabetes. Diabetes Care 37(8), 2334–2342 (2014). https://doi.org/10.2337/dc14-0225 CrossRefPubMed

19.

A.S. Krolewski, M.A. Niewczas, J. Skupien, T. Gohda, A. Smiles, J.H. Eckfeldt, A. Doria, J.H. Warram, Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care 37(1), 226–234 (2014). https://doi.org/10.2337/dc13-0985 CrossRefPubMed

20.

P.J. Saulnier, E. Gand, S. Ragot, G. Ducrocq, J.M. Halimi, C. Hulin-Delmotte, P. Llaty, D. Montaigne, V. Rigalleau, R. Roussel, G. Velho, P. Sosner, P. Zaoui, S. Hadjadj, Association of serum concentration of TNFR1 with all-cause mortality in patients with type 2 diabetes and chronic kidney disease: follow-up of the SURDIAGENE cohort. Diabetes Care 37(5), 1425–1431 (2014). https://doi.org/10.2337/dc13-2580 CrossRefPubMed

21.

J. Skupien, J.H. Warram, M.A. Niewczas, T. Gohda, M. Malecki, J.C. Mychaleckyj, A.T. Galecki, A.S. Krolewski, Synergism between circulating tumor necrosis factor receptor 2 and HbA(1c) in determining renal decline during 5-18 years of follow-up in patients with type 1 diabetes and proteinuria. Diabetes Care 37(9), 2601–2608 (2014). https://doi.org/10.2337/dc13-1983 CrossRefPubMedPubMedCentral

22.

M.E. Pavkov, R.G. Nelson, W.C. Knowler, Y. Cheng, A.S. Krolewski, M.A. Niewczas, Elevation of circulating TNF receptors 1 and 2 increases the risk of end-stage renal disease in American Indians with type 2 diabetes. Kidney Int. 87(4), 812–819 (2015). https://doi.org/10.1038/ki.2014.330 CrossRefPubMed

23.

E. Bae, R. H. Cha, Y. C. Kim, J. N. An, D. K. Kim, K. D. Yoo, S. M. Lee, M. H. Kim, J. T. Park, S. W. Kang, J. Y. Park, C. S. Lim, Y. S. Kim, S. H. Yang, J. P. Lee, Circulating TNF receptors predict cardiovascular disease in patients with chronic kidney disease. Medicine 96(19) (2017). https://doi.org/10.1097/MD.0000000000006666

24.

G. Fernández-Juárez, J. Villacorta Perez, J.L. Luño Fernández, E. Martinez-Martinez, V. Cachofeiro, V. Barrio Lucia, A.M. Tato Ribera, A. Mendez Abreu, A. Cordon, J.A. Oliva Dominguez, M. Praga Terente, High levels of circulating TNFR1 increase the risk of all-cause mortality and progression of renal disease in type 2 diabetic nephropathy. Nephrology 22(5), 354–360 (2017). https://doi.org/10.1111/nep.12781 CrossRefPubMed

25.

P.J. Saulnier, E. Gand, G. Velho, K. Mohammedi, P. Zaoui, M. Fraty, J. Michel Halimi, R. Roussel, S. Ragot, S. Hadjadj, Association of circulating biomarkers (Adrenomedullin, TNFR1, and NT-proBNP) with renal function decline in patients with type 2 diabetes: a French prospective cohort. Diabetes Care 40(3), 367–374 (2017). https://doi.org/10.2337/dc16-1571 CrossRefPubMed

26.

N.L. Baker, K.J. Hunt, D.R. Stevens, G. Jarai, G.D. Rosen, R.L. Klein, G. Virella, M.F. Lopes-Virella, Association between inflammatory markers and progression to kidney dysfunction: examining different assessment windows in patients with type 1 Diabetes. Diabetes Care 41(1), 128–135 (2018). https://doi.org/10.2337/dc17-0867 CrossRefPubMed

27.

E.L.M. Barr, F. Barzi, J.T. Hughes, G. Jerums, W.E. Hoy, K. O’Dea, G.R.D. Jones, P.D. Lawton, A.D.H. Brown, M. Thomas, E.I. Ekinci, A. Sinha, A. Cass, R.J. MacIsaac, L.J. Maple-Brown, High baseline levels of tumor necrosis factor receptor 1 are associated with progression of kidney disease in indigenous australians with diabetes: the eGFR follow-up study. Diabetes Care 41(4), 739–747 (2018). https://doi.org/10.2337/dc17-1919 CrossRefPubMed

28.

M. Nativel, F. Schneider, P. J. Saulnier, E. Gand, S. Ragot, O. Meilhac, P. Rondeau, E. Burillo, M. Cournot, L. Potier, G. Velho, M. Marre, R. Roussel, V. Rigalleau, K. Mohammedi, S. Hadjadj, Prognostic values of inflammatory and redox status biomarkers on the risk of major lower-extremity artery disease in individuals with type 2 Diabetes. Diabetes Care (2018). https://doi.org/10.2337/dc18-0695

29.

C. Nowak, A.C. Carlsson, C.J. Ostgren, F.H. Nystrom, M. Alam, T. Feldreich, J. Sundstrom, J.J. Carrero, J. Leppert, P. Hedberg, E. Henriksen, A.C. Cordeiro, V. Giedraitis, L. Lind, E. Ingelsson, T. Fall, J. Arnlov, Multiplex proteomics for prediction of major cardiovascular events in type 2 diabetes. Diabetologia 61(8), 1748–1757 (2018). https://doi.org/10.1007/s00125-018-4641-z CrossRefPubMedPubMedCentral

30.

N. Nowak, J. Skupien, A.M. Smiles, M. Yamanouchi, M.A. Niewczas, A.T. Galecki, K.L. Duffin, M.D. Breyer, N. Pullen, J.V. Bonventre, A.S. Krolewski, Markers of early progressive renal decline in type 2 diabetes suggest different implications for etiological studies and prognostic tests development. Kidney Int. 93(5), 1198–1206 (2018). https://doi.org/10.1016/j.kint.2017.11.024 CrossRefPubMedPubMedCentral

31.

J. Lin, F.B. Hu, C. Mantzoros, G.C. Curhan, Lipid and inflammatory biomarkers and kidney function decline in type 2 diabetes. Diabetologia 53(2), 263–267 (2010). https://doi.org/10.1007/s00125-009-1597-z CrossRefPubMed

32.

P.K. Bhatraju, L.R. Zelnick, M. Shlipak, R. Katz, B. Kestenbaum, Association of soluble TNFR-1 concentrations with long-term decline in kidney function: the multi-ethnic study of atherosclerosis. J. Am. Soc. Nephrol. 29(11), 2713–2721 (2018). https://doi.org/10.1681/ASN.2018070719 CrossRefPubMedPubMedCentral

33.

R.Z. Alicic, E.J. Johnson, K.R. Tuttle, Inflammatory mechanisms as new biomarkers and therapeutic targets for diabetic kidney disease. Adv. Chronic Kidney Dis. 25(2), 181–191 (2018). https://doi.org/10.1053/j.ackd.2017.12.002 CrossRefPubMed

34.

C.Q.F. Klessens, M. Zandbergen, R. Wolterbeek, J.A. Bruijn, T.J. Rabelink, I.M. Bajema, I.J. DHT, Macrophages in diabetic nephropathy in patients with type 2 diabetes. Nephrol. Dial. Transpl. 32(8), 1322–1329 (2017). https://doi.org/10.1093/ndt/gfw260 CrossRef

35.

A.S. Levey, L.A. Inker, K. Matsushita, T. Greene, K. Willis, E. Lewis, D. de Zeeuw, A.K. Cheung, J. Coresh, GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am. J. Kidney Dis. 64(6), 821–835 (2014). https://doi.org/10.1053/j.ajkd.2014.07.030 CrossRefPubMed

36.

M.E. Pavkov, E.J. Weil, G.D. Fufaa, R.G. Nelson, K.V. Lemley, W.C. Knowler, M.A. Niewczas, A.S. Krolewski, Tumor necrosis factor receptors 1 and 2 are associated with early glomerular lesions in type 2 diabetes. Kidney Int. 89(1), 226–234 (2016). https://doi.org/10.1038/ki.2015.278 CrossRefPubMedPubMedCentral

37.

K. Omote, T. Gohda, M. Murakoshi, Y. Sasaki, S. Kazuno, T. Fujimura, M. Ishizaka, Y. Sonoda, Y. Tomino, Role of the TNF pathway in the progression of diabetic nephropathy in KK-A(y) mice. Am. J. Physiol. Ren. Physiol. 306(11), F1335–F1347 (2014). https://doi.org/10.1152/ajprenal.00509.2013 CrossRef

38.

A.S. Awad, H. You, T. Gao, T.K. Cooper, S.A. Nedospasov, J. Vacher, P.F. Wilkinson, F.X. Farrell, W. Brian Reeves, Macrophage-derived tumor necrosis factor-alpha mediates diabetic renal injury. Kidney Int. 88(4), 722–733 (2015). https://doi.org/10.1038/ki.2015.162 CrossRefPubMedPubMedCentral

39.

G. Ramesh, W.B. Reeves, TNFR2-mediated apoptosis and necrosis in cisplatin-induced acute renal failure. Am. J. Physiol. Ren. Physiol. 285(4), F610–F618 (2003). https://doi.org/10.1152/ajprenal.00101.2003 CrossRef

40.

J.N. An, K.D. Yoo, J.H. Hwang, H.L. Kim, S.H. Kim, S.H. Yang, J.H. Kim, D.K. Kim, Y.K. Oh, Y.S. Kim, C.S. Lim, J.P. Lee, Circulating tumour necrosis factor receptors 1 and 2 predict contrast-induced nephropathy and progressive renal dysfunction: a prospective cohort study. Nephrology 20(8), 552–559 (2015). https://doi.org/10.1111/nep.12448 CrossRefPubMed

41.

A.C. Carlsson, L. Nordquist, T.E. Larsson, J.J. Carrero, A. Larsson, L. Lind, J. Arnlov, Soluble tumor necrosis factor receptor 1 is associated with glomerular filtration rate progression and incidence of chronic kidney disease in two community-based cohorts of elderly individuals. Cardiorenal Med 5(4), 278–288 (2015). https://doi.org/10.1159/000435863 CrossRefPubMedPubMedCentral

42.

H.C. Looker, R.G. Nelson, Reading the tree leaves-how to enrich clinical trials of diabetic kidney disease. Kidney Int. 92(1), 23–25 (2017). https://doi.org/10.1016/j.kint.2017.03.042 CrossRefPubMedPubMedCentral

43.

M. Yamanouchi, J. Skupien, M.A. Niewczas, A.M. Smiles, A. Doria, R.C. Stanton, A.T. Galecki, K.L. Duffin, N. Pullen, M.D. Breyer, J.V. Bonventre, J.H. Warram, A.S. Krolewski, Improved clinical trial enrollment criterion to identify patients with diabetes at risk of end-stage renal disease. Kidney Int. 92(1), 258–266 (2017). https://doi.org/10.1016/j.kint.2017.02.010 CrossRefPubMedPubMedCentral

44.

H.J.L. Heerspink, P. Perco, S. Mulder, J. Leierer, M.K. Hansen, A. Heinzel, G. Mayer, Canagliflozin reduces inflammation and fibrosis biomarkers: a potential mechanism of action for beneficial effects of SGLT2 inhibitors in diabetic kidney disease. Diabetologia 62(7), 1154–1166 (2019). https://doi.org/10.1007/s00125-019-4859-4 CrossRefPubMedPubMedCentral

45.

M.A. Niewczas, M.E. Pavkov, J. Skupien, A. Smiles, Z.I. Md Dom, J.M. Wilson, J. Park, V. Nair, A. Schlafly, P.J. Saulnier, E. Satake, C.A. Simeone, H. Shah, C. Qiu, H.C. Looker, P. Fiorina, C.F. Ware, J.K. Sun, A. Doria, M. Kretzler, K. Susztak, K.L. Duffin, R.G. Nelson, A.S. Krolewski, A signature of circulating inflammatory proteins and development of end-stage renal disease in diabetes. Nat. Med. 25(5), 805–813 (2019). https://doi.org/10.1038/s41591-019-0415-5 CrossRefPubMedPubMedCentral

46.

A. C. Carlsson, T. Ruge, E. Kjoller, J. Hilden, H. J. Kolmos, A. Sajadieh, J. Kastrup, G. B. Jensen, A. Larsson, C. Nowak, J. C. Jakobsen, P. Winkel, C. Gluud, J. Arnlov, 10-year associations between tumor necrosis factor receptors 1 and 2 and cardiovascular events in patients with stable coronary heart disease: a CLARICOR (effect of clarithromycin on mortality and morbidity in patients with ischemic heart disease) trial substudy. J. Am. Heart Assoc. 7(9) (2018). https://doi.org/10.1161/JAHA.117.008299

47.

K. Safranow, V. Dziedziejko, R. Rzeuski, E. Czyzycka, A. Wojtarowicz, A. Binczak-Kuleta, K. Jakubowska, M. Olszewska, A. Ciechanowicz, Z. Kornacewicz-Jach, B. Machalinski, A. Pawlik, D. Chlubek, Plasma concentrations of TNF-alpha and its soluble receptors sTNFR1 and sTNFR2 in patients with coronary artery disease. Tissue Antigens 74(5), 386–392 (2009). https://doi.org/10.1111/j.1399-0039.2009.01332.x CrossRefPubMed

48.

L. Nilsson, A. Szymanowski, E. Swahn, L. Jonasson, Soluble TNF receptors are associated with infarct size and ventricular dysfunction in ST-elevation myocardial infarction. PLoS ONE 8(2), e55477 (2013). https://doi.org/10.1371/journal.pone.0055477 CrossRefPubMedPubMedCentral

49.

R.S. Al-Lamki, A.P. Brookes, J. Wang, M.J. Reid, J. Parameshwar, M.J. Goddard, G. Tellides, T. Wan, W. Min, J.S. Pober, J.R. Bradley, TNF receptors differentially signal and are differentially expressed and regulated in the human heart. Am. J. Transpl. 9(12), 2679–2696 (2009). https://doi.org/10.1111/j.1600-6143.2009.02831.x CrossRef

50.

D. Luo, Y. Luo, Y. He, H. Zhang, R. Zhang, X. Li, W.L. Dobrucki, A.J. Sinusas, W.C. Sessa, W. Min, Differential functions of tumor necrosis factor receptor 1 and 2 signaling in ischemia-mediated arteriogenesis and angiogenesis. Am. J. Pathol. 169(5), 1886–1898 (2006). https://doi.org/10.2353/ajpath.2006.060603 CrossRefPubMedPubMedCentral

Title: Circulating TNF receptors and risk of renal disease progression, cardiovascular disease events and mortality in patients with diabetes: a systematic review and meta-analysis
Authors: Dongsheng Cheng
Yang Fei
Pierre-Jean Saulnier
Niansong Wang
Publication date: 01-04-2020
Publisher: Springer US
Keyword: Type 2 Diabetes
Published in: Endocrine / Issue 1/2020
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI: https://doi.org/10.1007/s12020-019-02153-y

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Heart Failure Video

Year in Review: Heart failure and cardiomyopathies

Watch now

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 1/2020

The expression of Tim-1 and Tim-4 molecules in regulatory T cells in type 1 diabetes

Exploring the molecular insights of concurrent composite mucoepidermoid carcinoma and papillary thyroid carcinoma

Acromegaly in the elderly patients

Selenium exerts protective effects against oxidative stress and cell damage in human thyrocytes and fibroblasts

Inhibition of thioredoxin 2 by intracellular methylglyoxal accumulation leads to mitochondrial dysfunction and apoptosis in INS-1 cells

Thyroid cancer: incidence and mortality trends in China, 2005–2015

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage